In Segment A, members will acquire various doses and schedules of oral ABBV-744 tablet to detect Risk-free dosing program. More participants is going to be enrolled at the recognized monotherapy dosign routine. In Section B, members will acquire oral ruxolitinib and ABBV-744 will probably be presented as "incorporate-on" therapy. In https://abbv-744-in-clinical-tria79124.liberty-blog.com/32127558/a-review-of-abbv-744-in-combination-with-immunotherapy